1,140 results match your criteria: "Italy C.H.; Clinica Sant'Anna[Affiliation]"

The Role of Crystalline Intermediates in Mechanochemical Cyclorhodation Reactions Elucidated by in-Situ X-ray Powder Diffraction and Computation.

Chemistry

September 2023

Instituto de Química, Facultad de Ciencias Exactas y Naturales Universidad de Antioquia, UdeA, Calle 70 No 52-21, Medellín, Colombia.

The occurrence of crystalline intermediates in mechanochemical reactions might be more widespread than previously assumed. For example, a recent study involving the acetate-assisted C-H activation of N-Heterocycles with [Cp*RhCl ] by ball milling revealed the formation of transient cocrystals between the reagents prior to the C-H activation step. However, such crystalline intermediates were only observed through stepwise intervallic ex-situ analysis, and their exact role in the C-H activation process remained unclear.

View Article and Find Full Text PDF

Carbon Dioxide Cycloaddition to Epoxides Promoted by Nicotinamidium Halide Catalysts: A DFT Investigation.

Chempluschem

July 2023

CEITEC - Central European Institute of Technology Central European, Institute of Technology, Purkyňova 123, Brno, 612 00, Czech Republic.

The utilization of CO as building block for the production of cyclic carbonate is a promising route to simultaneously mitigate the global warming issue and obtain valuable commercial chemicals. In this work, the activity of nicotinamidium halide catalysts towards the CO conversion into cyclic carbonate has been explored by means of density functional theory (DFT) calculations. DFT calculations support the ability, suggested experimentally, of the pyridium α-C-H proton of the catalysts to activate the epoxide ring via a hydrogen bond.

View Article and Find Full Text PDF

Leucopterin (CHNO) is the white pigment in the wings of Pieris brassicae butterflies, and other butterflies; it can also be found in wasps and other insects. Its crystal structure and its tautomeric form in the solid state were hitherto unknown. Leucopterin turned out to be a variable hydrate, with 0.

View Article and Find Full Text PDF

Language Delay in Patients with CLN2 Disease: Could It Support Earlier Diagnosis?

Neuropediatrics

December 2023

Rare and Complex Epilepsy Unit, Bambino Gesù Children's Hospital, IRCCS, Full Member of European Reference Network: EpiCARE, Rome, Italy.

Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare pediatric disorder associated with rapid neurodegeneration, and premature death in adolescence. An effective enzyme replacement therapy (cerliponase alfa) has been approved that can reduce this predictable neurological decline. The nonspecific early symptoms of CLN2 disease frequently delay diagnosis and appropriate management.

View Article and Find Full Text PDF

Effect of Hemodiafiltration or Hemodialysis on Mortality in Kidney Failure.

N Engl J Med

August 2023

From the Department of Nephrology and Hypertension (P.J.B., R.W.M.V.) and the Julius Center for Health Sciences and Primary Care (R.W.M.V., M.L.B.), University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; George Institute for Global Health, School of Public Health, Imperial College London (C.H., M.W.), and the Department of Renal Medicine, Royal Free Hospital, Division of Medicine, University College London (A.D.) - both in London; the Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari, Italy (G.F.M.S.); the School of Public Health, University of Sydney (G.F.M.S.), and the George Institute for Global Health, University of New South Wales (M.W.) - both in Sydney; Montpellier University School of Medicine, Montpellier, France (B.C.); Fresenius Medical Care Deutschland, Global Medical Office, Bad Homburg, Germany (B.C., K.C.), Medical Scientific Affairs, B. Braun Avitum, Melsungen (C.B.), and Charité Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and the Center of Internal Medicine and Dermatology, Department of Psychosomatic Medicine, Berlin Institute of Health, Berlin (K.C., M.R.) - all in Germany; the Division of Nephrology, Department of Clinical Sciences, Lund University, Lund (J.H.), and Corporate Medical Office Diaverum, Malmö (M.T.) - both in Sweden; and the Department of Nephrology, Grigore T. Popa University of Medicine, Iasi (A. Covic), and Fresenius Nephocare Dialysis Center, Bucharest (A. Cucui, A. Covic) - both in Romania.

Background: Several studies have suggested that patients with kidney failure may benefit from high-dose hemodiafiltration as compared with standard hemodialysis. However, given the limitations of the various published studies, additional data are needed.

Methods: We conducted a pragmatic, multinational, randomized, controlled trial involving patients with kidney failure who had received high-flux hemodialysis for at least 3 months.

View Article and Find Full Text PDF

Previous analyses of the phase 2 KEYNOTE-087 (NCT02453594) trial of pembrolizumab monotherapy demonstrated effective antitumor activity with acceptable safety in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL). However, long-term response durability and outcome of patients who receive a second course after treatment discontinuation after complete response (CR) remain of clinical interest. We present KEYNOTE-087 data after >5 years of median follow-up.

View Article and Find Full Text PDF

Background: Median survival with glioblastoma remains in the range of 12 months on population levels. Only few patients survive for more than 5 years. Patient and disease features associated with long-term survival remain poorly defined.

View Article and Find Full Text PDF

A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders.

Biomolecules

April 2023

Drug Design & Development Section, Translational Gerontology Branch, Intramural Research Program National Institute on Aging, Biomedical Research Center, 251 Bayview Blvd., NIH, Baltimore, MD 21224, USA.

The immunomodulatory imide drug (IMiD) class, which includes the founding drug member thalidomide and later generation drugs, lenalidomide and pomalidomide, has dramatically improved the clinical treatment of specific cancers, such as multiple myeloma, and it combines potent anticancer and anti-inflammatory actions. These actions, in large part, are mediated by IMiD binding to the human protein cereblon that forms a critical component of the E3 ubiquitin ligase complex. This complex ubiquitinates and thereby regulates the levels of multiple endogenous proteins.

View Article and Find Full Text PDF

Coinfection with and SARS-CoV-2: A Systematic Review.

Trop Med Infect Dis

April 2023

Department of Continuing Education, University of Oxford, Rewley House, 1 Wellington Square, Oxford OX1 2JA, UK.

Article Synopsis
  • The study reviews the impact of COVID-19 treatments, particularly steroids, on patients with co-infections such as strongyloidiasis, revealing potential exacerbation of the disease in those patients.
  • The research analyzed 16 studies that reported 25 cases of SARS-CoV-2 and strongyloidiasis coinfection, documenting various clinical presentations and treatment responses.
  • The findings indicate a significant number of patients experienced reactivation of strongyloidiasis likely due to COVID-19 treatments, underlining the need for more focused research on this interaction.
View Article and Find Full Text PDF
Article Synopsis
  • A study comparing endovascular therapy (EVT) and medical management (MM) for patients with isolated posterior cerebral artery occlusion found no significant difference in disability outcomes at 90 days.
  • EVT showed a greater likelihood of achieving a substantial improvement on the National Institutes of Health Stroke Scale and better overall recovery, despite higher risks of symptomatic intracranial hemorrhage (SICH) and mortality.
  • The findings suggest that while EVT may lead to better recovery, it comes with increased risks, indicating the need for careful patient selection in treatment decisions.
View Article and Find Full Text PDF

Non-destructive, fast, and accurate methods of dating are highly desirable for many heritage objects. Here, we present and critically evaluate the use of near-infrared (NIR) spectroscopic data combined with three supervised machine learning methods to predict the publication year of paper books dated between 1851 and 2000. These methods provide different accuracies; however, we demonstrate that the underlying processes refer to common spectral features.

View Article and Find Full Text PDF

A Dual-Chamber Leadless Pacemaker.

N Engl J Med

June 2023

From Amsterdam University Medical Centers, Amsterdam (R.E.K., K.T.N.B.); Icahn School of Medicine at Mount Sinai (V.Y.R.) and Weill Cornell Medicine-New York Presbyterian Hospital (J.E.I.) - both in New York; HonorHealth Cardiac Arrhythmia Group, Scottsdale, AZ (R.D.); Foothills Medical Centre, Calgary, AB, Canada (D.V.E.); Centre Hospitalier Régional Universitaire Albert Michallon, Grenoble, France (P.D.); Texas Cardiac Arrhythmia Institute, Austin (R.C.); Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy (M.G.B.); Tokyo Women's Medical University, Tokyo (M.S.); Deutsches Herzzentrum der Charité, Berlin (G.H.); Na Homolce Hospital, Prague, Czech Republic (V.Y.R., P.N.); Huntington Memorial Hospital, Pasadena (M.R.), and Abbott Medical, Sylmar (J.R.N., L.G., C.H.) - both in California; and the Cleveland Clinic, Cleveland (D.J.C.).

Article Synopsis
  • A dual-chamber leadless pacemaker system, involving devices placed in both the right atrium and right ventricle, aims to improve treatment options for patients needing pacemakers without the conventional wiring.
  • In a study of 300 patients, the new system demonstrated high safety, with 90.3% of participants avoiding serious complications within 90 days, which surpassed the target benchmark.
  • The effectiveness of the pacemaker was also confirmed, as 90.2% of patients achieved satisfactory atrial capture and sensing performance, indicating it can reliably support necessary heart functions.
View Article and Find Full Text PDF

Background: Digital measures offer an unparalleled opportunity to create a more holistic picture of how people who are patients behave in their real-world environments, thereby establishing a better connection between patients, caregivers, and the clinical evidence used to drive drug development and disease management. Reaching this vision will require achieving a new level of co-creation between the stakeholders who design, develop, use, and make decisions using evidence from digital measures.

Summary: In September 2022, the second in a series of meetings hosted by the Swiss Federal Institute of Technology in Zürich, the Foundation for the National Institutes of Health Biomarkers Consortium, and sponsored by Wellcome Trust, entitled "Reverse Engineering of Digital Measures," was held in Zurich, Switzerland, with a broad range of stakeholders sharing their experience across four case studies to examine how patient centricity is essential in shaping development and validation of digital evidence generation tools.

View Article and Find Full Text PDF

Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study.

Circ Heart Fail

May 2023

Université de Lorraine, Inserm, Centre d'Investigations Cliniques- Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France (N.G., K.D., J.P.F., A.P., A.-C.H., P.R., F.Z.).

Background: We sought to identify protein biomarkers of new-onset heart failure (HF) in 3 independent cohorts (HOMAGE cohort [Heart Omics and Ageing], ARIC study [Atherosclerosis Risk in Communities], and FHS [Framingham Heart Study]) and assess if and to what extent they improve HF risk prediction compared to clinical risk factors alone.

Methods: A nested case-control design was used with cases (incident HF) and controls (without HF) matched on age and sex within each cohort. Plasma concentrations of 276 proteins were measured at baseline in ARIC (250 cases/250 controls), FHS (191/191), and HOMAGE cohort (562/871).

View Article and Find Full Text PDF

Site-selective methylene C-H oxidation of an alkyl diamine enabled by supramolecular recognition using a bioinspired manganese catalyst.

Faraday Discuss

August 2023

Institut de Química Computacional i Catàlisi (IQCC) and Departament de Química, Universitat de Girona, Campus de Montilivi, 17071 Girona, Spain.

Site-selective oxidation of aliphatic C-H bonds is a powerful synthetic tool because it enables rapid build-up of product complexity and diversity from simple precursors. Besides the poor reactivity of alkyl C-H bonds, the main challenge in this reaction consists in differentiating between the multiple similar sites present in most organic molecules. Herein, a manganese oxidation catalyst equipped with two 18-benzo-6-crown ether receptors has been employed in the oxidation of the long chain tetradecane-1,14-diamine.

View Article and Find Full Text PDF

Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years.

Pharmacol Rev

September 2023

Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy (M.M.); European Center for Brain Research, Santa Lucia Foundation, Rome, Italy (M.M.); Canada Excellence Research Chair on the Microbiome-Endocannabinoidome Axis in Metabolic Health, University of Laval, Quebec, Canada (V.D.); Institute of Biochemistry and Molecular Medicine, NCCR TransCure, University of Bern, Bern, Switzerland (J.G.); Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland (U.G.); Department of Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, North Carolina (A.C.H.); iHuman Institute, ShanghaiTech University, Shanghai, China (T.H.); Center for Drug Discovery and Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts (A.M.); Departments of Pharmaceutical Sciences and Biological Chemistry, University of California, Irvine, California (D.P.); Department of Biochemistry, Kagawa University School of Medicine, Miki, Kagawa, Japan (N.U.); Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University, Leiden, Netherlands (M.S.).

The cannabis derivative marijuana is the most widely used recreational drug in the Western world and is consumed by an estimated 83 million individuals (∼3% of the world population). In recent years, there has been a marked transformation in society regarding the risk perception of cannabis, driven by its legalization and medical use in many states in the United States and worldwide. Compelling research evidence and the Food and Drug Administration cannabis-derived cannabidiol approval for severe childhood epilepsy have confirmed the large therapeutic potential of cannabidiol itself, Δ-tetrahydrocannabinol and other plant-derived cannabinoids (phytocannabinoids).

View Article and Find Full Text PDF

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.

N Engl J Med

May 2023

From the Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School - both in Boston (T.K.C.); the Department of Genitourinary Oncology, Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, London (T.P.); the Department of Cancer Medicine, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France (L.A.); Bradford Hill Clinical Research Center, Santiago (M.B.), and James Lind Centro de Investigación del Cáncer, Temuco (E.Y.R.) - both in Chile; the Postgraduate Medical Center, Department of Oncology, European Health Center, Otwock, Warsaw (C. Szczylik), and the Department of Outpatient Chemotherapy, Professor Franciszek Łukaszczyk Oncology Center, Bydgoszcz (B.Z.) - both in Poland; Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IRCCS, Padua, Italy (M.M.); Consultorio de Medicina Especializada, Benito Juárez, Mexico City (A.S.Z.); Instituto de Oncología de Rosario, Rosario, Argentina (L.E.F.); Latin American Cooperative Oncology Group, Porto Alegre, and Beneficência Portuguesa de São Paulo, São Paulo - both in Brazil (F.A.S.); the Department of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada (D.Y.C.H.); Exelixis, Alameda, CA (F.W., F.M., Y.-L.C.); Bristol Myers Squibb, Boudry, Switzerland (M.K.L.); the Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Barcelona (C. Suarez); and the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York (R.J.M.).

Background: The efficacy and safety of treatment with cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal-cell carcinoma are unknown.

Methods: In this phase 3, double-blind trial, we enrolled patients with advanced clear-cell renal-cell carcinoma who had not previously received treatment and had intermediate or poor prognostic risk according to the International Metastatic Renal-Cell Carcinoma Database Consortium categories. Patients were randomly assigned to receive 40 mg of cabozantinib daily in addition to nivolumab and ipilimumab (experimental group) or matched placebo in addition to nivolumab and ipilimumab (control group).

View Article and Find Full Text PDF

The zeolitic imidazolate framework, ZIF-4, exhibits soft porosity and is known to show pore volume changes with temperatures, pressures, and guest adsorption. However, the mechanism and adsorption behavior of ZIF-4 are not completely understood. In this work, we report an open to narrow pore transition in ZIF-4 around ∼ 253 K upon lowering the temperature under vacuum (10 Torr) conditions, facilitated by C-H···π interactions.

View Article and Find Full Text PDF

2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance.

Eur Heart J

July 2023

Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, UK.

This 2023 statement updates clinical guidance for homozygous familial hypercholesterolaemia (HoFH), explains the genetic complexity, and provides pragmatic recommendations to address inequities in HoFH care worldwide. Key strengths include updated criteria for the clinical diagnosis of HoFH and the recommendation to prioritize phenotypic features over genotype. Thus, a low-density lipoprotein cholesterol (LDL-C) >10 mmol/L (>400 mg/dL) is suggestive of HoFH and warrants further evaluation.

View Article and Find Full Text PDF

Background: Advances in treatment have enabled patients with haemophilia A to live longer and therefore may be subjected to comorbidities associated with ageing, in addition to disease-associated morbidities. There have been few reports to date on efficacy and safety of treatment specifically in patients with severe haemophilia A and comorbidities.

Objective: To explore the efficacy and safety of damoctocog alfa pegol prophylaxis in patients with severe haemophilia A aged ⩾40 years with comorbidities of interest.

View Article and Find Full Text PDF

Cu-loaded zeolites enable the selective activation of ethane to ethylene at low temperatures and pressure.

Chem Commun (Camb)

May 2023

Centre for Materials Science and Nanotechnology (SMN), Department of Chemistry, University of Oslo, 1033 Blindern, 0315, Oslo, Norway.

Cu-zeolites are found to activate the C-H bond of ethane already at 150 °C in a cyclic protocol and form ethylene with a high selectivity. Both the zeolite topology and Cu content are found to impact the ethylene yield. Ethylene adsorption studies with FT-IR, demonstrate that oligomerization of ethylene occurs over protonic zeolites, while this reaction does not occur over Cu-zeolites.

View Article and Find Full Text PDF

Cerebral Oximetry Monitoring in Extremely Preterm Infants.

N Engl J Med

April 2023

From the Departments of Neonatology (M.L.H., G.H.H., M.I.S.R., G.G.) and Intensive Care (S.H.-S.), Copenhagen Trial Unit, Center for Clinical Intervention Research, the Capital Region (M.H.O., C.G., J.C.J.), and the Department of Neuroanesthesiology, Neuroscience Center (M.H.O.), Copenhagen University Hospital-Rigshospitalet, and the Section of Biostatistics, Department of Public Health, University of Copenhagen (A.K.G.J.), Copenhagen, the Neonatal Intensive Care Unit, Aarhus University Hospital, Aarhus (P.A.), the Department of Neonatology, Aalborg University Hospital, Aalborg (L.B.), and the Department of Pediatrics, Odense University Hospital (A.K.), and the Department of Regional Health Research, the Faculty of Health Sciences, University of Southern Denmark (C.G., J.C.J.), Odense - all in Denmark; the Department of Neonatology, La Paz University Hospital (A.P., M.M.Y., E.V., R.S.-S.), the Neonatology Department, 12 de Octubre University Hospital (S.P.-B., C.M.-B., E.B.-S.), the Department of Neonatology, Instituto del Nino y del Adolescente, Hospital Clinico San Carlos-Instituto de Investigación Sanitaria San Carlos (L.A.), Madrid, the Department of Neonatology, Hospital Clínic Barcelona, BCNatal-Barcelona Center for Maternal-Fetal and Neonatal Medicine (M.A.-C., M.T.-P.), and the Department of Neonatology, Hospital Sant Joan de Deu (R.R.F., A.A.), Barcelona, the Neonatal Unit, Marqués de Valdecilla University Hospital, and the Department of Medical and Surgical Sciences, Cantabria University, Santander (I.C.), the Neonatal Intensive Care Unit, Puerta del Mar University Hospital, Cádiz (P.Z.), the Department of Neonatology, Hospital Universitario de Tarragona Juan XXIII, Tarragona (O.O.V.), the Neonatal Unit, University Hospital Virgen de las Nieves, Granada (L.S.L.), the Division of Neonatology, University Hospital Cruces, Biocruces Health Research Institute, Barakaldo (B.L.G.), and the Neonatology Division, Miguel Servet University Hospital, Zaragoza (I.S.-V.) - all in Spain; the Division of Newborn Medicine, Gazi University Hospital (E.E., M. Baş), and the Department of Neonatology, NICU, University of Health Sciences, Ankara City Hospital (S.S.O., M.S.A.), Ankara, the Department of Neonatology, Bursa Uludag University Faculty of Medicine, Bursa (H.O., N.K.), the Division of Neonatology, Department of Pediatrics, Marmara University Research and Education Hospital, Marmara University, School of Medicine (A.C.M., S.G.K.), and the Department of Neonatology, Kanuni Sultan Suleyman Training and Research Hospital (B.Y., M.C.), Istanbul, and Basaksehir Cam and Sakura City Hospital, Basaksehir (B.Y., M.C.) - all in Turkey; the 2nd Department of Neonatology, Neonatal Biophysical Monitoring and Cardiopulmonary Therapies Research Unit, Poznan University of Medical Sciences, Poznan (T.S.), the Department of Neonatology, Centrum Medyczne Ujastek (B.R.-W., E.R.-W.), and the Department of Neonatology, Jagiellonian University Hospital (R.L.), Krakow, Warsaw University of Medical Sciences (A.B.) and the Neonatology Department, Center of Postgraduate Medical Education (M.W.), Warsaw, the Neonatal Unit, Specialist Hospital No. 2, Bytom (S.M.), the Department of Neonatology, Collegium Medicum in Bydgoszcz Nicolaus Copernicus University in Torun, Bydgoszcz (I.S.-K.), and the Department of Neonatology, Wroclaw Medical University, Wroclaw (B.K.-O.) - all in Poland; Pediatric Intensive Care and Neonatology, Children's University Hospital of Zurich (C.H.), and the Department of Neonatology, University Hospital Zurich (T.K., C.K.), Zurich, the Intensive Care Unit, Children's Hospital Lucerne, Lucerne (M.S., A.H.), the Clinic of Neonatology, Department of Women, Mother and Child, University Hospital Center, and the University of Lausanne, Lausanne (A.C.T.), and the Division of Neonatology and Pediatric Intensive Care, Children's University Hospital of Geneva, and University of Geneva, Geneva (O.B.) - all in Switzerland; the Department of Development and Regeneration Katholieke Universiteit Leuven, Leuven (G.N., L.T., A.S.), Service de Néonatologie, Clinique Centre Hospitalier Chrétien Montlégia-Liège-Belgium, Liege (P.M.), the Department of Neonatology, Grand Hôpital de Charleroi, Charleroi (C.L.), NICU, Tivoli Hospital, La Louviere (J. Buyst), and the Department of Neonatology, Algemeen Ziekenhuis St.-Jan Bruges, Bruges (L. Cornette) - all in Belgium; the Department of Pediatrics, Division of Newborn Medicine, Mountainside Medical Center, Montclair, NJ (J. Mintzer); Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (M.F., F.M., S.P.), the Department of Clinical Sciences and Community Health, University of Milan (M.F., F.M.), Milan, Unità Operativa Complessa di Neonatologia, Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome (G.V.), the Department of Neonatology, Neonatal Intensive Care Unit and Pediatrics, Filippo Del Ponte Hospital, University of Insubria, Varese (M.A.), and Struttura Complessa Neonatologia, Osp. S.Anna-Città della Salute e della Scienza di Torino, Turin (E.M.) - all in Italy; NICU, Department of Pediatrics, Patras Medical School, Patras (G.D., E.S.), the 1st Department of Neonatology of Aristotle University of Thessaloniki, Ippokrateion General Hospital of Thessaloniki, Thessaloniki (K.S., K.T.), the Neonatal Intensive Care Unit, Alexandra University and State Maternity Hospital, Athens (E.P.), and the Department of Neonatology and NICU, University Hospital of Heraklion, Heraklion (E.H.) - all in Greece; the Infant Centre and Department of Paediatrics and Child Health, University College Cork, Cork (E.D., D.H.), and the School of Medicine, Department of Paediatrics, Royal College of Surgeons in Ireland (A.E.-K.), National Maternity Hospital (A.C.), Coombe Women and Infant University Hospital (J. Miletin), and Ireland University College Dublin (J. Miletin), Dublin - all in Ireland; the Department of Neonatology, University Hospital Motol (J.T., V.K.), and the Institute for the Care of Mother and Child (J.Š., J. Miletin, P.K., J.K.) and the Third Faculty of Medicine, Charles University (J.Š., P.K.), Prague - all in Czechia; the Department of Neonatology, Children's Hospital of Fudan University, Shanghai (G.C., Z.P., L.W.), the Department of Neonatology, Longgang District Central Hospital, Shenzen (S.Z.), the Department of Neonatology, Maternal and Child Health Hospital of Zhuang Autonomous Region, Quangxi (X.G.), the Department of Neonatal Intensive Care Unit, Children's Hospital of Zhejiang University School of Medicine, Hangzhou (L.H.), the Department of Neonatology, Hainan Women and Children's Medical Center, Haikou (L.Y.), the Department of Neonatology, Xiamen Children's Hospital, Xiamen (X.X.), and the Department of Neonatology, the People's Hospital of Dehong, Mangshi (Z.Y.) - all in China; the Department of Neonatology, Oslo University Hospital, Oslo (S.F., T.N.); the Department of Neonatal Medicine, Royal Hospital for Children, Glasgow (A.M.H.), and the Neonatology Department, University Hospital Wishaw, Wishaw (K.M.) - both in the United Kingdom; the Department of Pediatrics (G.P., B.U.) and the Research Unit for Neonatal Micro- and Macrocirculation (G.P.), Medical University of Graz, Graz, Austria; the Division of Neonatology and Pediatric Intensive Care Medicine, Center for Pediatrics and Adolescents Medicine, Medical Center-University of Freiburg, and the Faculty of Medicine, University of Freiburg, Freiburg, Germany (H.F., J. Baumgartner); the Department of Neonatology, St. John's Medical College, Bangalore, India (S.N., S.A.R.); the Division of Neonatology, Department of Pediatrics, Loma Linda University Children's Hospital, Loma Linda, CA (A.O.H., M.M.K.); the Division of Neonatology, University of Utah Hospital, Salt Lake City (M. Baserga); the Department of Pediatrics, Division of Newborn Medicine, Washington University School of Medicine, St. Louis (Z.V.); INSERM Unité 1141, University of Paris, Paris (O.B.); and the Division of Pediatrics-Neonatal-Perinatal, UT Southwestern, Dallas (L. Chalak).

Background: The use of cerebral oximetry monitoring in the care of extremely preterm infants is increasing. However, evidence that its use improves clinical outcomes is lacking.

Methods: In this randomized, phase 3 trial conducted at 70 sites in 17 countries, we assigned extremely preterm infants (gestational age, <28 weeks), within 6 hours after birth, to receive treatment guided by cerebral oximetry monitoring for the first 72 hours after birth or to receive usual care.

View Article and Find Full Text PDF

The New European Medical Device Regulation: Balancing Innovation and Patient Safety.

Ann Intern Med

June 2023

Clinical Effectiveness Research Group, University of Oslo, and Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway, and Showa University Northern Yokohama Hospital, Digestive Disease Center, Yokohama, Japan (Y.M.).

Article Synopsis
  • * "Expert panels" are created to help assess devices for certification, and the role of "notified bodies" is expanded to ensure manufacturers comply with the new standards.
  • * All existing medical devices must be recertified by 2027 or 2028, creating uncertainty for manufacturers and highlighting the need for better collaboration between the industry and healthcare professionals to avoid device shortages and support the development of new devices.
View Article and Find Full Text PDF

Background: Definitions are essential for effective communication and discourse, particularly in science. They allow the shared understanding of a thought or idea, generalization of knowledge, and comparison across scientific investigation. The current terms describing olfactory dysfunction are vague and overlapping.

View Article and Find Full Text PDF
Article Synopsis
  • Momelotinib is the first inhibitor targeting both JAK1, JAK2, and ACVR1, showing benefits in treating symptoms of myelofibrosis (MF), like splenomegaly and anemia.
  • A long-term analysis pooled data from three phase 3 studies involving 725 MF patients, with some remaining on momelotinib for over 5 years.
  • The treatment had a manageable safety profile, with diarrhea as the most common side effect, and no increase in serious adverse events over time.
View Article and Find Full Text PDF